SWX:ROGPharmaceuticals
Roche Obesity Drug Data Adds Fresh Angle To Valuation Debate
Roche Holding (SWX:ROG) reported positive topline Phase II results for CT-388, its investigational dual GLP-1/GIP receptor agonist for obesity treatment.
The trial showed significant and clinically meaningful weight loss outcomes, along with a promising efficacy and safety profile.
For Roche, best known for its pharmaceuticals and diagnostics businesses, CT-388 adds focus to its cardiometabolic pipeline at a time when obesity treatments are drawing strong global attention. GLP-1 and GIP...